Investigation of Objective Cognitive Effort in Neuropsychological Evaluation of Psychotic Disorders (INVESTIGECCO)

January 17, 2025 updated by: University Hospital, Montpellier

Psychotic disorders are characterised by a heterogeneity of symptoms, including cognitive disorders, which predict functional outcome. To date, the evaluation of cognitive functions essentially measures performance. Cognitive effort and the influence of psychological factors are rarely considered.

Based on the principle of energy conservation, the Motivational Intensity Theory (MIT) allows to test cognitive effort independently of performance, by measuring cardiovascular reactivity, as well as controlling for psychological factors (e.g., mood, fatigue, anxiety).

The main aim of this study is to investigate in a memory task the interaction between cognitive effort, performance and psychological factors in individuals with psychotic disorders compared to a non-clinical group, based on the predictions of the MIT.

This study will provide insights into the nature of cognitive impairment in psychotic disorders: primary or secondary to motivational (effort) or psychological (mood, fatigue, anxiety) difficulties.

Study Overview

Detailed Description

The study will be proposed to patients with psychotic disorders (n=50) and non clinical participants (n = 50) aged 18 to 60.

This is a non-interventional, randomized, prospective experimental study with mixed design: 2 groups (psychotic disorders vs. non-clinical) with 2 repeated measures of difficulty (easy vs. difficult).

The study comprises a single visit with memory tests recording cardiovascular, and performance data, as well as participants' perceptions of the task (effort invested, difficulty, motivation to perform the task), followed by a psychological assessment using questionnaires and a semi-structured interview.

The study of these different measures (cardiovascular, performance, perception) will enable us to refine the understanding of cognitive deficits in psychotic disorders, taking psychopathological variables into account. will provide better direction for the care of this population: cognitive remediation for primary cognitive disorders vs. cognitive and behavioral therapies for cognitive disorders secondary to psychopathological variables (mood, fatigue, defeatist beliefs, motivational deficits).

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Montpellier, France, 34295
        • Montpellier University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Non-clinical group: Absence of any psychiatric disorder, community sample

Psychotic disorders group : Patients with a diagnosis within the schizophrenia spectrum and other psychotic disorders according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA, 2015), selected from the adult psychiatry department, inpatient or outpatient hospitalisation

Description

Inclusion Criteria in both groups

- Age ≥ 18 years and ≤60 years

Inclusion criteria for the psychotic disorders group:

- Patients with a diagnosis within the schizophrenia spectrum and other psychotic disorders according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA, 2015).

Inclusion criterion for the non-clinical group:

- Absence of any psychiatric disorder.

non-inclusion criteria in both groups

  • Neurological disorder or history of head trauma;
  • Cardiovascular disease or treatment for hypertension;
  • Substance abuse or dependence disorder;
  • Individuals who cannot understand or speak French;
  • Non-affiliation with a social security system;
  • Individuals participating in another study that includes an ongoing exclusion period;
  • Individuals who have not provided written informed consent to participate in the study;
  • Pregnant or breastfeeding women;
  • Absence of written consent from the legal guardian for patients under guardianship;
  • Absence of notification to the curator for patients under curatorship.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
psychotic disorders

The target population is people with a psychotic disorder (diagnosed as schizophrenia or schizoaffective disorder) according to DSM 5 criteria, aged between 18 and 60.

The people with psychotic disorders recruited for this study are currently being cared for at the adult psychiatry department of Montpellier University Hospital.

Participants will have a single visit with memory tests and data recording (cardiovascular, performance, perceptions), followed by a psychological assessment using questionnaires and a semi-structured interview.

Measurement of pre-ejection period is the period between the onset of electrical excitation of the left ventricle and the opening of the aortic valve and heart rate will be continuous.

These data will be collected using a cardiograph measuring the ECG signal and impedance cardiography (ICG). The system's four electrodes are positioned on the middle axillary line at the end of the sternum and at the base of the neck.

Blood pressure measurements (PAS and PAD) will be taken from a cuff placed on the brachial artery of the non-dominant arm.

cardiovascular values will be measured continuously:

  • Each participant rested while watching a documentary for 8 minutes.
  • During two 5-minute memory tasks of different difficulty levels (easy and difficult), separated by a 5-minute break.

The averages of the last 5 minutes during the resting period will constitute the resting values, and the averages of the 5 minutes of each difficulty level will constitute the values during cognitive effort.

First, a quiet period with the viewing of a documentary film (8min).

Then, participants will perform two 5-minute memory tasks of different difficulty levels (memorizing 3 letters corresponds to the easy level vs. 7 letters to the difficult level), separated by a 5-minute break. The order of difficulty will be counterbalanced.

At the end of each difficulty level, self-report measures assessed by the following questions will be collected:

  • "How much effort did you exert during the task?";
  • How difficult did you find the task?
  • How motivated were you to perform the task? Responses will be in Likert scale format, ranging from 1 ("no effort at all", "very easy", "not at all motivated", respectively) to 7 ("a lot of effort", "very difficult", "very motivated", respectively).

psychopathological measures collected using questionnaires:

  • Beck Depression Inventory (BDI-II): mood
  • State-Trait Anxiety Inventory (Form Y) (STAY-Y): anxiety
  • Multidimensional Fatigue Inventory, 20-item version (MFI-20=): fatigue
  • General Self-Efficacy Scale (GSES): defeatist beliefs
  • Clinical Assessment Interview for Negative Symptoms (CAINS) : psychotic symptoms for the psychotic disorders group
non clinical, control

The non-clinical population should be similar to the psychotic disorders population in terms of age, level of education and gender.

Participants will have a single visit with memory tests and data recording (cardiovascular, performance, perceptions), followed by a psychological assessment using questionnaires and a semi-structured interview.

Measurement of pre-ejection period is the period between the onset of electrical excitation of the left ventricle and the opening of the aortic valve and heart rate will be continuous.

These data will be collected using a cardiograph measuring the ECG signal and impedance cardiography (ICG). The system's four electrodes are positioned on the middle axillary line at the end of the sternum and at the base of the neck.

Blood pressure measurements (PAS and PAD) will be taken from a cuff placed on the brachial artery of the non-dominant arm.

cardiovascular values will be measured continuously:

  • Each participant rested while watching a documentary for 8 minutes.
  • During two 5-minute memory tasks of different difficulty levels (easy and difficult), separated by a 5-minute break.

The averages of the last 5 minutes during the resting period will constitute the resting values, and the averages of the 5 minutes of each difficulty level will constitute the values during cognitive effort.

First, a quiet period with the viewing of a documentary film (8min).

Then, participants will perform two 5-minute memory tasks of different difficulty levels (memorizing 3 letters corresponds to the easy level vs. 7 letters to the difficult level), separated by a 5-minute break. The order of difficulty will be counterbalanced.

At the end of each difficulty level, self-report measures assessed by the following questions will be collected:

  • "How much effort did you exert during the task?";
  • How difficult did you find the task?
  • How motivated were you to perform the task? Responses will be in Likert scale format, ranging from 1 ("no effort at all", "very easy", "not at all motivated", respectively) to 7 ("a lot of effort", "very difficult", "very motivated", respectively).

psychopathological measures collected using questionnaires:

  • Beck Depression Inventory (BDI-II): mood
  • State-Trait Anxiety Inventory (Form Y) (STAY-Y): anxiety
  • Multidimensional Fatigue Inventory, 20-item version (MFI-20=): fatigue
  • General Self-Efficacy Scale (GSES): defeatist beliefs
  • Clinical Assessment Interview for Negative Symptoms (CAINS) : psychotic symptoms for the psychotic disorders group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Interaction effect of group x difficulty on cardiovascular reactivity (Pre-Ejection Period - PEP)
Time Frame: 18 minutes
The difference score between the pre-ejection period (PEP) during the task (easy and difficult) and the PEP at rest (i.e., baseline), expressed in ms.
18 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Investigation of systolic blood pressure in both groups and difficulties
Time Frame: 18 minutes
expressed in mmHg
18 minutes
Investigation of diastolic blood pressure in both groups and difficulties
Time Frame: 18 minutes
expressed in mmHg
18 minutes
Investigation of heart rate pressure in both groups and difficulties
Time Frame: 18 minutes
expressed in beats/minutes
18 minutes
Comparison of correct performance
Time Frame: 10 minutes
The percentage of correct responses between the two groups and in both levels of difficulty
10 minutes
Comparison of errors
Time Frame: 10 minutes
The rate of errors between the two groups and in both levels of difficulty
10 minutes
Comparison of self-reported effort in both groups and both difficulties
Time Frame: 1 minute

Self-reported effort will assess through the following question:

- "How much effort did you exert during the task?" Response will be on a Likert scale ranging from 1 ('Not at all effort') to 7 ('A lot of effort').

1 minute
Comparison of self-reported difficulty in both groups and both difficulties
Time Frame: 1 minute

Self-reported difficulty will assess through the following question:

"How difficult did you find the task?" Response will be on a Likert scale ranging from 1 ('Very easy') to 7 ('Very difficult').

1 minute
Comparison of self-reported motivation in both groups and both difficulties
Time Frame: 1 minute

Self-reported motivation will assess through the following question:

"How motivated were you to complete the task?" Response will be on a Likert scale ranging from 1 ('Not at all motivated') to 7 ('Very motivated').

1 minute
Influence of depressed mood on effort
Time Frame: 5 minutes

Beck Depression Inventory (BDI-II, Beck et al., 1996, internal consistency α = .92). This self-administered questionnaire consists of 21 items, each scored from 0 to 3. The total score ranges from 0 to 63.

The higher the score, the more severe the depression.

5 minutes
Influence of anxiety on effort
Time Frame: 5 minutes
State-Trait Anxiety Inventory (Form Y) (STAY-Y, Spielberger et al., 1983, Bruchon-Schweitzer & Paulhan, 1993 for French validation, internal consistency α = .91). The STAY-Y assesses two scales momentary anxiety and trait anxiety, each comprising 20 items. Scores range from 1 ("Not at all for the momentary anxiety scale, "Almost never" for the trait anxiety scale) to 4 ("A lot", "Almost always", respectively). The higher the score, the more severe the anxiety.
5 minutes
Influence of fatigue on effort
Time Frame: 3 minutes
Multidimensional Fatigue Inventory, 20-item version (IMF-20, Smets et al., 1995, Gentille et al., 2003 for French validation, internal consistency α > .70). This scale comprises 20 items ranging from 1 ("Strongly disagree") to 5 ("Strongly agree").The total score is between 4 and 20, the higher the score, the greater the fatigue felt.The MFI has 5 subscales: general fatigue, mental fatigue, reduced motivation, physical fatigue, reduced activities.
3 minutes
Influence of defeatist beliefs on effort
Time Frame: 3 minutes
General Self-Efficacy Scale (GSES, Schwarzer & Jerusalem, 1995, Dumont et al., 2000, for French validation, internal consistency α > .76).This scale measures feelings of self-efficacy . This scale measures feelings of self-efficacy (the opposite of defeatist beliefs). It comprises 10 items, scored on a Likert scale ranging from 1 ("Not at all true") to 4 ("Totally true"). The higher the score, the higher the sense of self-efficacy, and the lower the person's self-defeating beliefs.
3 minutes
Influence of negatives symptomes on effort in schizophrenia group
Time Frame: 30 minutes

Clinical Assessment Interview for Negative Symptoms (CAINS, Kring et al., 2013; Laraki et al., 2022 for French validation, internal consistency α = 0.87). This is a semi-structured interview assessing the negative symptoms of schizophrenia.

This interview is composed of 13 items ranging from 0 (absence/no deficit) to 5 (severe deficit). The interview includes two subscales: motivation and pleasure (MAP, 9 items) and expressivity (EXP, 4 items).

30 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Amandine Décombe, PhD, University Hospital, Montpellier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 27, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

December 10, 2024

First Submitted That Met QC Criteria

January 17, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 17, 2025

Last Verified

August 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychotic Disorders

Clinical Trials on Cardiovascular measurements

Subscribe